alendronate has been researched along with Kidney Diseases in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pamidronate was comparable to alendronate in prevention of early bone loss after kidney transplantation." | 2.76 | Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation. ( Alasti, M; Beladi Mousavi, SS; Ghorbani, A; Omidvar, B; Shahbazian, H; Shariat Nabavi, SJ, 2011) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "To review the product information (PI) for various brands of the same generic drugs and investigate the extent to which information is currently available on dosing in renal impairment and the concordance between the dosing recommendations for the same generic drug." | 1.40 | Renal drug dosing recommendations: evaluation of product information for brands of the same drug. ( Castelino, RL; Jose, MD; Khanal, A; Peterson, GM, 2014) |
| "Alendronate treatment appeared to have a similar effect on surrogate markers in postmenopausal osteoporotic Japanese women with or without RD." | 1.38 | Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study. ( Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Uzawa, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iseri, K | 1 |
| Iyoda, M | 1 |
| Watanabe, M | 1 |
| Matsumoto, K | 1 |
| Sanada, D | 1 |
| Inoue, T | 1 |
| Tachibana, S | 1 |
| Shibata, T | 1 |
| Khanal, A | 1 |
| Peterson, GM | 1 |
| Castelino, RL | 1 |
| Jose, MD | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Omidvar, B | 1 |
| Ghorbani, A | 1 |
| Shahbazian, H | 1 |
| Beladi Mousavi, SS | 1 |
| Shariat Nabavi, SJ | 1 |
| Alasti, M | 1 |
| Iwamoto, J | 1 |
| Sato, Y | 1 |
| Uzawa, M | 1 |
| Takeda, T | 1 |
| Matsumoto, H | 1 |
| SoRelle, R | 1 |
| Hoefle, G | 1 |
| Holzmueller, H | 1 |
| Drexel, H | 1 |
1 review available for alendronate and Kidney Diseases
| Article | Year |
|---|---|
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
2 trials available for alendronate and Kidney Diseases
| Article | Year |
|---|---|
The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Denosumab; | 2018 |
Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents; Bone Den | 2011 |
4 other studies available for alendronate and Kidney Diseases
| Article | Year |
|---|---|
Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Topics: Administration, Oral; Alendronate; Cardiovascular Agents; Central Nervous System Agents; Contraindic | 2014 |
Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without renal dysfunction: a retrospective study.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Fe | 2012 |
Two markers complement each other in identifying risk.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Alendronate; Biomarkers; C-Reactive Protein; Calcitr | 2004 |
Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation.
Topics: Alendronate; Bone Resorption; Calcitriol; Calcium; Cyclosporine; Drug Therapy, Combination; Heart Tr | 2004 |